Clinical Trial Accrual Targeting Genomic Alterations After Next-Generation Sequencing at a Non-National Cancer Institute–Designated Cancer Program We distributed a 21-item survey on cancer screening ...
The novel drug appeared effective in healthy, previously untreated patients, but cost, side effects, and other issues may stand in the way of its widespread use. Compared with German and US patients, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results